Group 1 - The core viewpoint of the article highlights a significant increase in credit bond issuance in the primary market, with a total of 332 bonds issued, amounting to 312.27 billion yuan, representing a 306.00% increase compared to the previous period [4][5] - In terms of issuance scale, industrial bonds accounted for 135.37 billion yuan, a 295.92% increase, while urban investment bonds reached 138.91 billion yuan, a 409.86% increase, together making up 43.35% and 44.48% of the total issuance respectively [4][5] - The average issuance term for credit bonds was 2.73 years, with industrial bonds averaging 1.88 years and urban investment bonds averaging 3.24 years [4] Group 2 - The average coupon rate for credit bonds was 2.22%, with industrial bonds at 2.06%, urban investment bonds at 2.32%, and financial bonds at 1.71% [5] - In the secondary market, credit spreads varied by industry, with the largest increase in AAA-rated food and beverage sector by 2.1 basis points, while the largest decrease was in the communication sector by 8.3 basis points [6] - The total trading volume of credit bonds reached 1,403.85 billion yuan, a 121.26% increase, with commercial bank bonds, corporate bonds, and medium-term notes being the top three in trading volume [7]

Core Viewpoint - The copper market is expected to remain tight in 2026, supporting upward price movement despite current demand pressures [4]. Supply and Demand - As of January 9, 2026, SHFE copper closed at 101,410 CNY/ton, up 3.23% from January 2, while LME copper closed at 12,998 USD/ton, up 4.31% [4]. - The TC spot price has hit a record low, indicating tight procurement of copper concentrate [4]. - Domestic copper social inventory increased by 14.6% week-on-week, while LME copper inventory decreased by 2.5% [5]. - The copper supply from China in October 2025 was 130,000 tons, down 8.1% month-on-month and 12.1% year-on-year [6]. Inventory Levels - Domestic mainstream port copper concentrate inventory was 640,000 tons as of January 9, 2026, down 0.8% from the previous week [5]. - Global electrolytic copper inventory totaled 838,000 tons, up 6.2% from December 31 [5]. Smelting and Processing - The TC spot price was -45.1 USD/ton as of January 9, 2026, marking a historical low [7]. - China's electrolytic copper production in December 2025 was 1.1781 million tons, up 6.8% month-on-month and 7.5% year-on-year [7]. Demand Trends - Cable manufacturing, which accounts for approximately 31% of domestic copper demand, saw a weekly operating rate of 56.58%, down 2.37 percentage points [9]. - Air conditioning production, representing about 13% of domestic copper demand, is projected to decline by 11.4% in January to March 2026 [9]. Futures Market - As of January 9, 2026, SHFE copper active contract positions decreased by 12.8% week-on-week, with a total of 189,000 contracts [10]. - COMEX non-commercial net long positions were 58,000 contracts, down 3.3% from the previous week [10].

本周（2026.01.05-2026.01.09，下同）A股"开门红"，主要宽基指数均实现大幅上涨。市场情绪方面，主要 宽基指数量能指标有所提振，量能择时模型纷纷发出看多信号；主要宽基指数及宽基指数ETF期权持仓量 PCR、成交量PCR震荡回落，市场风险偏好进一步提升。资金面方面，融资增加额环比大幅提升，资金面 表现持续乐观；股票型ETF的资金流入方向有所分化，中小盘ETF资金净流入积极。 点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 本周市场核心观点与市场复盘： 本周南向资金净流入326.94亿港元，其中沪市港股通净流入119.66亿港元，深市港股通净流入207.28亿港 元。 风险偏好提振背景下，市场有望实现进一步上行，春季躁动行情仍可期。中长线持续看好"红利+科技" ...

Group 1: Small Nucleic Acid Drugs - Small nucleic acid drugs, primarily SiRNA and ASO, are entering a rapid growth phase from technological breakthroughs to large-scale commercialization [2] - The global market for small nucleic acid drugs grew from $0.1 billion in 2016 to $3.25 billion in 2021, with a compound annual growth rate (CAGR) of 217.8% [2] - It is projected that the global oligonucleotide drug market will exceed $15 billion by 2026, with a CAGR of 35% from 2020 to 2025 [2] Group 2: Blue Sky Technology - Blue Sky Technology has established a comprehensive "synthesis-purification" supply capability for small nucleic acids (siRNA/ASO) and peptide drugs [3] - The company has developed proprietary solid-phase synthesis materials and has built a technical platform that integrates high-difficulty oligonucleotide synthesis and impurity separation [3] - Blue Sky Technology plans to invest 1.15 billion yuan to build a GMP/like GMP standard biopharmaceutical industrial park and has established a subsidiary in Sweden to enhance global technical collaboration [3] Group 3: Lianhua Technology - Lianhua Technology is rapidly expanding into the small nucleic acid business, leveraging its established small molecule CDMO system [4] - The global CDMO/CMO market is expected to exceed $120 billion by 2024, with a CAGR of approximately 9.5% [4] - The company has made significant progress in international market expansion and has deepened R&D collaborations with leading global pharmaceutical companies [4]

Market Overview - During the period from January 5 to January 9, 2026, the secondary market prices of publicly listed REITs in China increased, with the China Securities REITs closing at 793.05 and the China Securities REITs total return index at 1028.93, reflecting returns of 1.86% and 1.89% respectively [4] - Compared to other major asset classes, the return rates ranked as follows: convertible bonds > A-shares > gold > REITs > US stocks > crude oil > pure bonds [4] - Both property and concession-type REITs saw price increases, with property-type REITs yielding a return of 2.48% and concession-type REITs yielding 1.69% [4] - The municipal facilities REITs had the highest increase in returns, with the top three asset types being municipal facilities, new infrastructure, and water conservancy facilities [4] Trading Activity - The total trading volume for public REITs during this period was 3.55 billion yuan, with new infrastructure REITs leading in average daily turnover rate at 0.70% [5] - The top three REITs by trading volume were CICC ProLogis REIT, Jianxin Zhongguancun REIT, and Guotai Junan Chengtou Kuan Ting Rental Housing REIT, while the top three by trading value were Huaxia China Resources Commercial REIT, CICC Anhui Jiaokong REIT, and Huaxia China Communications Construction REIT [5] - The net inflow of capital during this period was 19.501 million yuan, indicating increased market trading enthusiasm compared to the previous period [5] Block Trading - The total amount of block trading during this period was 154 million yuan, which was a decrease from the previous period [6] - There were five trading days with block trades, with the highest single-day block trading amount reaching 38.98 million yuan on January 7, 2026 [6] - The top three REITs by block trading value were Guangfa Chengdu Gaotou Industrial Park REIT, CICC ProLogis Consumption REIT, and CICC Hubei Keti Guanggu REIT [6] Primary Market - No new REIT products were listed during this period [7] - The project status of four REIT products was updated [7]

Overall Viewpoint - This week, there were multiple supply-side events in the new energy sector: (1) Four ministries held a symposium on power and energy storage battery industries to regulate industry competition; (2) The "anti-involution" trend in the photovoltaic sector was influenced by market information, leading to a continuous decline in polysilicon futures; (3) Export tax rebates for photovoltaic products will be canceled starting April 1, 2026, while battery product export tax rates will gradually decrease to a cancellation by 2027. The new energy industry's "anti-involution" is inherently complex and challenging, with the state aiming to maintain international competitiveness. Balancing market and policy adjustments will evolve accordingly. Therefore, the direction of the photovoltaic industry's "anti-involution" will not change, focusing more on execution coordination and method restructuring; the battery industry is more about preventive reminders against energy storage battery oversupply; the adjustment of export tax rebate policies is expected to optimize the supply side, potentially leading to a short-term export rush [4]. Investment Perspective - (1) Market enthusiasm is currently focused on commercial aerospace and space computing, with wind power stocks such as Goldwind Technology, Taisheng Wind Energy, and Mingyang Smart Energy, as well as photovoltaic stocks like Junda Co., Oriental Sunrise, and Maiwei Co., having accumulated significant price increases, detaching from their core business fundamentals, making it inadvisable to chase high prices at this time [4]. - (2) AI power: There is optimism regarding domestic computing power demand rebounding after the NVIDIA H200 release; the HVDC solution is expected to ramp up, and SST technology and collaboration progress are likely to materialize; this can also align with AI applications to form sector rotation; the capital expenditure situation for North American data centers in 2027 needs to be assessed during the US stock annual report period for risk evaluation [4]. - (3) During the "14th Five-Year Plan" period, based on the dual benefits of China's future industries and the EU carbon tariff in 2026, there is optimism for the coordinated, large-scale, and advanced construction of hydrogen, ammonia, and methanol [5]. - (4) For energy storage/lithium battery upstream: The overall game on the lithium battery demand side is focused on domestic energy storage bidding in 2026; data on energy storage and vehicle terminals still need to be tracked, making it difficult to confirm or refute; the investment ranking for lithium battery materials is: lithium carbonate > lithium hexafluorophosphate > aluminum foil > separator > copper foil > anode; lithium carbonate prices still have upward momentum in the short term [5].

Group 1: Market Overview - The A-share market experienced a strong start to the year, with major indices showing significant increases, indicating a rise in market risk appetite [5] - The financing amount increased significantly, reflecting a continued optimistic performance in the market [5] - The spring market rally is anticipated to continue, supported by improved market sentiment [5] Group 2: Fixed Income - In the credit bond market, 332 bonds were issued with a total issuance scale of 312.27 billion, marking a 30.6% increase compared to the previous period [6] - Credit spreads varied across industries, with the largest increase in the food and beverage sector (up 2.1 basis points) and the largest decrease in the telecommunications sector (down 8.3 basis points) [6] Group 3: Commodities - The TC spot price reached a historical low, indicating ongoing tightness in copper concentrate procurement, while domestic social inventory continues to grow [7] - Despite the pressure on demand from rising copper prices, the supply-demand situation is expected to remain tight, with a positive outlook for copper prices in 2026 [7] Group 4: Chemical Industry - The small nucleic acid drug market is projected to experience rapid growth in 2026, with key players like Bluestar Technology and Lonza leading breakthroughs in critical areas [8] - The Chinese Ministry of Commerce has introduced measures against Japan, increasing the urgency for domestic substitution of key semiconductor materials [8] Group 5: Renewable Energy and Environmental Protection - The photovoltaic industry is expected to focus on coordination and method restructuring, while the battery industry is advised to prevent oversupply in energy storage batteries [9] - Investment opportunities are identified in domestic computing power, hydrogen energy, and upstream energy storage sectors, with a positive outlook for lithium carbonate prices in the short term [9]

Core Viewpoint - The report highlights the performance of various market factors and investment strategies over the week of January 5 to January 9, 2026, indicating a mixed performance across different factors and sectors, with notable trends in momentum and valuation factors [4][5][6]. Factor Performance - Major factors such as beta, residual volatility, and size factors yielded positive returns of 1.07%, 1.02%, and 0.59% respectively, while the momentum factor showed a significant negative return of -1.08% [4]. - In the CSI 300 stock pool, the best-performing factors included 5-day average turnover rate (4.90%), relative turnover volatility (4.59%), and quarterly revenue growth rate (3.92%), while the worst performers were momentum-adjusted large orders (-1.11%), ROA stability (-1.15%), and ROE stability (-1.43%) [5]. - In the CSI 500 stock pool, the top factors were gross margin TTM (1.29%), quarterly net profit growth rate (1.09%), and total asset growth rate (0.81%), with the worst being price-to-book ratio (-3.51%), TTM price-to-earnings ratio inverse (-4.06%), and price-to-earnings ratio (-4.69%) [5]. - In the liquidity 1500 stock pool, the best factors were gross margin TTM (2.17%), quarterly revenue growth rate (2.14%), and quarterly operating profit growth rate (1.85%), while the worst were the correlation of intraday volatility with transaction amount (-2.64%), price-to-earnings ratio (-3.01%), and TTM price-to-earnings ratio inverse (-3.18%) [5]. Industry Factor Performance - The net asset growth rate factor performed well in the non-bank financial and diversified sectors, while the net profit growth rate factor excelled in the diversified sector [6]. - The per-share net asset factor showed strong performance in the real estate and beauty care sectors, and the per-share operating profit TTM factor performed well in the diversified sector [6]. - The 5-day momentum factor exhibited momentum effects in media, communication, steel, and pharmaceutical sectors, while showing reversal effects in coal and agriculture sectors [6]. - Valuation factors like BP performed well in real estate and leisure services, while EP performed well in banking and non-bank financial sectors [7]. Investment Strategy Performance - The PB-ROE-50 combination achieved significant excess returns in the CSI 800 and overall market stock pools, with excess returns of 1.36% in the CSI 800 and 1.23% in the overall market, but a negative excess return of -2.18% in the CSI 500 stock pool [8]. - The private equity research tracking strategy generated positive excess returns, while the public equity research stock selection strategy had a relative excess return of -0.31% compared to the CSI 800 [9]. - The block trading combination achieved an excess return of 0.69% relative to the CSI All Index [10]. - The targeted issuance combination experienced a pullback in excess returns, with a relative excess return of -1.58% compared to the CSI All Index [11].

Core Viewpoint - The article discusses the revolutionary shift in small nucleic acid drugs, highlighting their potential to transition from symptomatic treatment to addressing root causes, marking a significant advancement in the pharmaceutical industry [4]. Group 1: Small Nucleic Acid Drug Technology - Small nucleic acid drugs (siRNA, ASO, etc.) are considered the "third wave" of drug development, following small molecules and antibody drugs [4]. - These drugs are not limited by their molecular structure and can target a broader range of disease pathways, significantly increasing the probability of successful drug development [4]. - Current advancements in delivery technologies and chemical modifications have led to extended half-lives for these drugs, improving patient compliance in chronic disease management [4]. Group 2: Market Growth and Commercialization - The global small nucleic acid drug market is projected to reach $20.6 billion by 2029 and $54.9 billion by 2034, with a compound annual growth rate (CAGR) of 21.6% [5]. - Major players like Alnylam, Ionis, and Arrowhead are leading the market, with multinational corporations (MNCs) such as Novartis and Roche investing heavily in this sector [5]. - Alnylam's core product, Amvuttra, is expected to exceed $2 billion in sales by 2025, indicating strong market performance [6]. Group 3: Technological Breakthroughs - Arrowhead has developed RNAi therapies targeting various diseases through its TRiM platform, expanding the application of small nucleic acid drugs beyond liver diseases [7]. - Avidity Biosciences has made significant progress in muscle tissue delivery using antibody-oligonucleotide conjugates (AOC) technology, indicating a broader therapeutic potential [7]. Group 4: China's Small Nucleic Acid Drug Industry - The Chinese small nucleic acid drug industry is experiencing a qualitative leap, overcoming delivery patent barriers and demonstrating global competitiveness in target selection and molecular design [8]. - A complete industrial chain has emerged in China, with domestic raw materials achieving localization, thus reducing R&D costs [8]. - Significant business development (BD) transactions have occurred, including a record $5 billion deal between Wobang Pharmaceutical and Novartis, showcasing the global recognition of Chinese innovation [8].

以下文章来源于债券人 ，作者光大证券固收研究 本周（2026年1月5日至2026年1月9日，共5个交易日）中证转债指数涨跌幅为+4.45%（上周涨跌幅 为-0.27%），中证全指变动为+5.04%（上周涨跌幅为-0.32%）。2026年以来中证转债涨跌幅为+4.45%， 中证全指涨跌幅为+5.04%。 分评级来看，债项评级高评级券（评级为AAA）、中高评级券（评级为AA+）、中评级券（评级为 AA）、中低评级券（评级为AA-）和低评级券（评级为AA-及以下）本周涨跌幅分别为+1.37%、+2.50% 、+5.16%、+4.83%、+4.10%，中评级券涨幅最高。 债券人 . 唯有进行扎实的基本面研究，方能行稳致远。 点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客 户，用作新媒体形势下研究信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿 订阅、接收或使用本订阅号中的任何信息。本订阅号难以设置访问权限，若给您造成不便， 敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相关人员为光大 证券的客户。 报告摘要 1、市场 ...